Unique challenges faced by the clinical evaluation of dengue vaccines

References

• Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st Century. Trends Microbiol.10(2), 100–103 (2002).
   PubMedGoogle Scholar
• Freedman DO, Weld LH, Kozarsky PE et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N. Engl. J. Med.354(2), 119–130 (2006).
   PubMed Web of Science ®Google Scholar
• DeRoeck D, Deen J, Clemens JD. Policymakers’ views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four Southeast Asian countries. Vaccine22(1), 121–129 (2003).
   PubMed Web of Science ®Google Scholar
• Hombach J, Barrett AD, Cardosa MJ et al. Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26–27 April 2004, Bangkok, Thailand. Vaccine23(21), 2689–2695 (2005).
   PubMedGoogle Scholar
• Letson GW, Singhasivanon P, Fernandez E et al. Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas. Hum. Vaccin.6(10), 30–37 (2010).
   Google Scholar
• Edelman R, Whitehead S, Vaughn DW. Vaccine strategies to prevent dengue. In: New Generation Vaccines. Levine MM, Dougan G, Good MF et al. (Eds). Informa Healthcare USA Inc., NY, USA, 593–602 (2010).
   Google Scholar
• Sabin A. Research on dengue in World War II. Am. J. Trop. Med.1, 30–50 (1952).
   PubMedGoogle Scholar
• Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J. Biol. Med.42(5), 311–328 (1970).
   PubMed Web of Science ®Google Scholar
• Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am. J. Trop. Med. Hyg.42(2), 179–184 (1990).
   PubMed Web of Science ®Google Scholar
• Huang KJ, Yang YC, Lin YS et al. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J. Immunol.176(5), 2825–2832 (2006).
   PubMed Web of Science ®Google Scholar
• Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science239(4839), 476–481 (1988).
   PubMed Web of Science ®Google Scholar
• Avirutnan P, Punyadee N, Noisakran S et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein ns1 and complement. J. Infect. Dis.193(8), 1078–1088 (2006).
   PubMed Web of Science ®Google Scholar
• Chanthavanich P, Luxemburger C, Sirivichayakul C et al. Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am. J. Trop. Med. Hyg.75(1), 26–28 (2006).
   PubMed Web of Science ®Google Scholar
• Guy B, Chanthavanich P, Gimenez S et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine22(27–28), 3563–3574 (2004).
   PubMed Web of Science ®Google Scholar
• Gibbons RV, Kalanarooj S, Jarman RG et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am. J. Trop. Med. Hyg.77(5), 910–913 (2007).
   PubMed Web of Science ®Google Scholar
• Hombach J, Cardosa MJ, Sabchareon A, Vaughn DW, Barrett AD. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17–18 November 2005. Vaccine25(21), 4130–4139 (2007).
   PubMed Web of Science ®Google Scholar
• Berger R, Just M. Interference between strains in live virus vaccines. II: combined vaccination with varicella and measles–mumps–rubella vaccine. J. Biol. Stand.16(4), 275–279 (1988).
   PubMedGoogle Scholar
• Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev. Infect. Dis.13(5), 926–939 (1991).
   PubMedGoogle Scholar
• Sabchareon A, Lang J, Chanthavanich P et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am. J. Trop. Med. Hyg.66(3), 264–272 (2002).
   PubMed Web of Science ®Google Scholar
• Kitchener S, Nissen M, Nasveld P et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine24(9), 1238–1241 (2006).
   PubMed Web of Science ®Google Scholar
• Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J. Infect. Dis.201(3), 370–377 (2010).
   PubMed Web of Science ®Google Scholar
• Guy B, Barban V, Mantel N et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am. J. Trop. Med. Hyg.80(2), 302–311 (2009).
   PubMed Web of Science ®Google Scholar
• Edelman R, Wasserman SS, Bodison SA et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am. J. Trop. Med. Hyg.69(6 Suppl.), 48–60 (2003).
   PubMed Web of Science ®Google Scholar
• Sun W, Cunningham D, Wasserman SS et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum. Vaccin.5(1), 33–40 (2009).
   PubMed Web of Science ®Google Scholar
• Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev. Panam. Salud Publica11(4), 223–227 (2002).
   PubMedGoogle Scholar
• Edelman R, Hombach J. “Guidelines for the clinical evaluation of dengue vaccines in endemic areas”: summary of a World Health Organization Technical Consultation. Vaccine26(33), 4113–4119 (2008).
   PubMedGoogle Scholar
• Guirakhoo F, Pugachev K, Zhang Z et al. Safety and efficacy of chimeric yellow fever–dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol.78(9), 4761–4775 (2004).
   PubMed Web of Science ®Google Scholar
• Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine18(Suppl. 2), 26–32 (2000).
   PubMed Web of Science ®Google Scholar
• Endy TP, Nisalak A, Chunsuttitwat S et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis.189(6), 990–1000 (2004).
   PubMed Web of Science ®Google Scholar